Amneal Pharmaceuticals (AMRX) Revenue (2017 - 2026)

Amneal Pharmaceuticals has reported Revenue for 10 years, with the latest figure at $796.2 million in Q2 2026.

• On a quarterly basis, Revenue rose 9.89% year-over-year to $796.2 million in Q2 2026; TTM through Jun 2026 was $3.1 billion, a 9.28% increase from a year earlier, with the FY2025 full-year figure at $3.0 billion, up 8.05% from the prior year.
• Revenue was $796.2 million for Q2 2026 at Amneal Pharmaceuticals, up from $722.5 million in the prior quarter.
• The five-year high for Revenue was $814.3 million in Q4 2025, with the low at $497.6 million in Q1 2022.
• Average Revenue over 5 years is $663.2 million, with a median of $677.3 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Revenue grew 0.92% in 2022, then grew 18.4% in 2024.
• Over 5 years, Revenue stood at $609.8 million in 2022, then climbed by 1.18% to $617.0 million in 2023, then climbed by 18.4% to $730.5 million in 2024, then gained by 11.47% to $814.3 million in 2025, then retreated by 2.23% to $796.2 million in 2026.
• The last three Revenue figures came in at $796.2 million (Q2 2026), $722.5 million (Q1 2026), and $814.3 million (Q4 2025), per Business Quant data.